StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
LOTUSEYE.NS$108.18+0.25%
Fair $108.18+0.0%

LOTUSEYE.NS

Lotus Eye Hospital and Institute Limited

Healthcare / Medical Care FacilitiesNSE

$108.18

+0.27 (+0.25%)

Fairly Valued+0.0%Fair Value $108.18Fund rank 24/100 · Data gapFallback financials|
SA 40/C
F-Score: 3/9
Margin CompressionLow Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $-21.3M · quality 43.7/100

Data gap 24/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 6/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

40/100

C

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 2unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Operating margin has declined for 3 consecutive years ROE is 0.1%, below the 5% threshold
Thesis & Journal · LOTUSEYE.NSLocal privado en este navegador · Lotus Eye Hospital and Institute Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$2.2B

P/E

349.0x

↑

EV/EBITDA

50.8x

↑

ROE

0.1%

↓

Gross Margin

48.7%

↑

Debt/Equity

0.26

↑
52-Week Range$108
$68$147

TradingView lightweight chart

LOTUSEYE.NS price, volumen y niveles de valoración

Último $108.57Periodo +204.5%
Fair value: $108.18

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2023–2026 · 3 años de histórico normalizado

Revenue CAGR

+5.3%

FCF CAGR

—

FCF margin

-18.7%

FCF / Net income

-124.71x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $537.1M · net income $804000.0 · FCF $-100.3M

2023-FY → 2026-FY

Gross margin

48.7%-1.9% pts

Operating margin

-0.7%-10.9% pts

Net margin

0.1%-8.7% pts

FCF margin

-18.7%-21.5% pts
MetricTTM
2026
2025
2024
2023
Income Statement
Revenue$537.1M$537.1M$495.6M$472.4M$459.8M
Net Income$804000.00$804000.00$7.4M$29.1M$40.8M
EBITDA$45.5M$45.5M$47.4M$78.4M$87.3M
EPS0.040.040.361.401.96
Gross Margin48.7%48.7%49.8%49.6%50.6%
Operating Margin-0.7%-0.7%0.9%6.2%10.2%
Net Margin0.1%0.1%1.5%6.2%8.9%
Balance Sheet
Debt/Equity0.260.260.060.020.01
Cash Flow
Free Cash Flow$-100.3M$-100.3M$-21.3M$403000.00$12.9M
Returns
ROE0.1%0.1%1.2%4.9%7.1%
Valuation
P/E348.97348.97188.7543.9632.73
EV/EBITDA50.8250.8229.7116.1314.95
P/B3.623.622.332.152.32
Growth & Yield
Revenue Growth8.4%8.4%4.9%2.7%—
EPS Growth-88.9%-88.9%-74.3%-28.6%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

521.4%

muy exigente

EPS terminal req.

$9.60

Spread vs growth

-610.3%

5Y implied EPS CAGR

210.9%

muy exigente

EPS terminal req.

$11.61

Spread vs growth

-299.8%

10Y implied EPS CAGR

84.9%

muy exigente

EPS terminal req.

$18.71

Spread vs growth

-173.8%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +48.3%

Total return

+48.3%

Start / end P/E

203.4x → 2714.2x

EPS bridge

0.36 → 0.04

Residual

-1097.5%

EPS growth-88.9%
Multiple rerating+1234.7%
Dividend+0.0%
Residual / FX / buybacks / cross-term-1097.5%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.